UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Blood, ISSN 0006-4971, 01/2018, Volume 131, Issue 2, pp. 155 - 156
Journal Article
British journal of haematology, ISSN 0007-1048, 11/2020
Journal Article
Biochemical pharmacology, ISSN 0006-2952, 2011, Volume 81, Issue 7, pp. 881 - 890
MLN8237 | Aurora A and B | Mantle cell lymphoma (MCL) | Aurora Inhibitor | Non-Hodgkin lymphoma (NHL) | Docetaxel | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Pharmacology. Drug treatments | Taxoids - pharmacology | Apoptosis - drug effects | Pyrimidines - administration & dosage | Humans | Lymphoma, Mantle-Cell - pathology | Aurora Kinases | Pyrimidines - pharmacology | Mice, SCID | Aurora Kinase A | Azepines - pharmacology | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Animals | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Azepines - administration & dosage | Index Medicus
Journal Article
Clinical lymphoma, myeloma and leukemia, ISSN 2152-2650, 09/2020, Volume 20, pp. S34 - S36
Journal Article
Leukemia, ISSN 0887-6924, 08/2015, Volume 29, Issue 8, pp. 1702 - 1712
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Apoptosis - drug effects | Tissue Array Analysis | Humans | Myeloid Cell Leukemia Sequence 1 Protein - metabolism | Lymphoma, Large B-Cell, Diffuse - metabolism | Immunoenzyme Techniques | Proto-Oncogene Proteins c-bcl-2 - metabolism | Female | Tumor Cells, Cultured | Real-Time Polymerase Chain Reaction | Myeloid Cell Leukemia Sequence 1 Protein - antagonists & inhibitors | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | RNA, Messenger - genetics | Antineoplastic Combined Chemotherapy Protocols | Mice, SCID | Reverse Transcriptase Polymerase Chain Reaction | Sulfonamides - pharmacology | Myeloid Cell Leukemia Sequence 1 Protein - genetics | Drug Synergism | Lymphoma, Large B-Cell, Diffuse - mortality | Xenograft Model Antitumor Assays | Pyridinium Compounds - pharmacology | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Animals | Mice, Inbred NOD | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Cell Proliferation - drug effects | Mice | Proto-Oncogene Proteins c-bcl-2 - genetics | Proteins | Chemical inhibitors | Leukemia research | Dosage and administration | Research | Non-Hodgkin's lymphomas | Drug therapy | Health aspects | Apoptosis | Drugs | Animal models | Risk groups | Cyclin-dependent kinases | Xenotransplantation | Risk | Myc protein | Kinases | Lymphoma | Patients | Mcl-1 protein | Anticancer properties | Cyclin-dependent kinase | Chemotherapy | Lymphocytes B | Xenografts | Antitumor activity | Inhibition | B-cell lymphoma | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 05/2008, Volume 26, Issue 14, pp. 2258 - 2263
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lymphoma, B-Cell - radiotherapy | Male | Cyclophosphamide - adverse effects | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Lymphoma, B-Cell - drug therapy | Prednisone - administration & dosage | Antibodies, Monoclonal, Murine-Derived | Prednisone - adverse effects | Rituximab | Combined Modality Therapy | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, B-Cell - pathology | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects | Index Medicus
Journal Article
American journal of hematology, ISSN 0361-8609, 04/2018, Volume 93, Issue 4, pp. 486 - 493
Life Sciences & Biomedicine | Hematology | Science & Technology | Antimitotic agents | Broadway theater | Care and treatment | Chemotherapy | Lymphomas | Product development | Antineoplastic agents | Cancer | Histone deacetylase | Chromatin | Statistical analysis | Cell survival | Transcription | Toxicity | Rituximab | Lymphoma | Hypotheses | Lymphocytes B | Sepsis | Acetylation | Histocompatibility | Neutropenia | Index Medicus | vorinostat | histone deacetylase inhibitor | diffuse large B-cell lymphoma
Journal Article
Haematologica (Roma), ISSN 0390-6078, 06/2012, Volume 97, Issue 6, pp. 937 - 942
Combined monoclonal antibody | FCGR | Follicular lymphoma | Chemotherapy | SWOG | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Lymphoma, Follicular - therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Lymphoma, Follicular - diagnosis | Lymphoma, Follicular - mortality | Rituximab | Antibodies, Monoclonal - therapeutic use | Genotype | Male | Receptors, IgG - genetics | Lymphoma, Follicular - immunology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Adult | Female | Aged | Combined Modality Therapy - methods | Polymorphism, Single Nucleotide | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Index Medicus | Original and Brief Reports | follicular lymphoma | chemotherapy | combined monoclonal antibody
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 07/2017, Volume 35, Issue 20, pp. 2260 - 2267
Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Recurrence | Cytarabine - therapeutic use | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Male | Transplantation, Autologous | Methotrexate - therapeutic use | Lymphoma, B-Cell - genetics | Cyclophosphamide - therapeutic use | Stem Cell Transplantation | Female | Ifosfamide - therapeutic use | Etoposide - therapeutic use | Survival Rate | Remission Induction | Cytarabine - administration & dosage | Proto-Oncogene Proteins c-bcl-6 - genetics | Disease-Free Survival | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Methotrexate - administration & dosage | Proto-Oncogene Proteins c-myc - genetics | Proto-Oncogene Proteins c-bcl-2 - genetics | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Index Medicus | ORIGINAL REPORTS
Journal Article
Molecular imaging, ISSN 1536-0121, 4/2016, Volume 15, p. 153601211664543
mTOR inhibition | extracellular pH | CEST MRI | therapy response | lymphoma | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Biochemical Research Methods | Science & Technology | Cell Survival - drug effects | Everolimus - pharmacology | TOR Serine-Threonine Kinases - metabolism | Acidosis - diagnostic imaging | Humans | Lymphoma, Mantle-Cell - drug therapy | Magnetic Resonance Imaging - methods | Molecular Imaging - methods | Everolimus - administration & dosage | Acidosis - metabolism | TOR Serine-Threonine Kinases - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Tumor Burden - drug effects | Hydrogen-Ion Concentration - drug effects | Cell Line, Tumor | Lymphoma, Mantle-Cell - chemistry | Mice | Gene Expression Regulation, Neoplastic - drug effects | Lymphoma, Mantle-Cell - metabolism | TOR protein | Biotechnology | Statistical analysis | Growth rate | Xenotransplantation | AKT protein | Rapamycin | Malignancy | Kinases | pH effects | Lymphoma | 1-Phosphatidylinositol 3-kinase | Anticancer properties | Cell activation | Magnetic resonance imaging | Lymphocytes B | Mantle cell lymphoma | Xenografts | In vivo methods and tests | Mantle | Tumors | Index Medicus
Journal Article
International journal of cancer, ISSN 0020-7136, 06/2012, Volume 130, Issue 12, pp. 2997 - 3005
non‐Hodgkin lymphoma | mantle cell lymphoma | AT9283 | aurora kinase inhibitor | docetaxel | non-Hodgkin lymphoma | Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Taxoids - pharmacology | Apoptosis - drug effects | Humans | Lymphoma, Mantle-Cell - drug therapy | Aurora Kinases | Mice, SCID | Xenograft Model Antitumor Assays | Aurora Kinase B | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Urea - analogs & derivatives | Lymphoma, B-Cell - pathology | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Line, Tumor | Benzimidazoles - pharmacology | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Cell Cycle - drug effects | Urea - pharmacology | Lymphoma, B-Cell - drug therapy | Index Medicus
Journal Article